Full-Time

Research Study Activation Specialist

Updated on 8/1/2026

Tennessee Oncology

Tennessee Oncology

501-1,000 employees

Community-based cancer care with clinical research

No salary listed

Nashville, TN, USA

In Person

Category
Biology & Biotech (1)
Required Skills
FDA Regulations

Get referred to Tennessee Oncology

See people who can refer or advise you

Requirements
  • A bachelor's degree in a health, science, or related field is required; in lieu of a degree, six years of directly related clinical research experience may be considered.
  • One year of relevant previous research experience is required.
  • Knowledge of Good Clinical Practice, International Council for Harmonisation guidelines, Food and Drug Administration regulations, and institutional policies governing human subject research is required.
  • ACRP or SOCRA certification is required; research certification must be obtained after one year and no later than 18 months after employment.
  • Knowledge of organizational policies, procedures, and systems is required.
  • Understanding of clinical research principles, regulatory guidelines, Food and Drug Administration requirements, Good Clinical Practice, and the study start-up process is required.
  • The role requires the ability to work independently, prioritize tasks, multitask in a fast-paced environment, identify and resolve study activation issues, maintain meticulous attention to detail, and collaborate with diverse teams.
  • The role requires strong written and verbal communication skills for interacting with various stakeholders.
Responsibilities
  • Lead and manage the end-to-end study activation process, including feasibility assessment, site selection, and site initiation readiness.
  • Develop, track, and maintain activation timelines, milestones, and deliverables to ensure on-time study activation.
  • Schedule, coordinate, and participate in pre-study and site initiation visits.
  • Facilitate communications between the contract research organization or sponsor and appropriate internal staff during study activation.
  • Ensure activation activities comply with Good Clinical Practice, institutional policies, standard operating procedures, and applicable regulatory requirements.
  • Ensure consistency between site standard operating procedures and study requirements.
  • Ensure required study documents are collected, reviewed, and approved before site initiation.
  • Identify activation risks and barriers and proactively implement mitigation strategies.
  • Coordinate with regulatory, budget and contracting, pharmacy, laboratory, tissue, data, and clinical operations teams to meet activation requirements.
  • Facilitate activation meetings and ensure clear communication of expectations, responsibilities, and timelines.
  • Serve as the primary point of contact for sponsors and contract research organizations for study start-up activities.
  • Track and report activation metrics, including time to activation, bottlenecks, and workload distribution.
  • Identify opportunities to improve activation workflows, standardize processes, and reduce start-up timelines.
  • Support implementation of new activation procedures, tools, and training initiatives.
  • Comply with Institutional Review Board and Independent Ethics Committee requirements.
  • Confirm appropriate staff, facility, and equipment availability during study activation.
  • Track regulatory submission status and communicate updates to relevant parties.
  • Maintain detailed records of study activation progress, including timelines, milestones, and challenges encountered.
  • Prepare reports for internal and external stakeholders.
  • Review, establish, and agree on project plans and project timelines.
  • Ensure monitoring measures are in place and implement contingency plans as needed.
  • Maintain direct contact with sponsors on specific initiatives as needed.
  • Perform other duties as assigned.
Desired Qualifications
  • Experience in oncology research or with a contract research organization or sponsor is preferred.

Tennessee Oncology runs a large network of community-based cancer care with a strong clinical-trial program. It delivers cancer treatment at local clinics, including on-site chemotherapy, and uses molecular diagnostics to tailor therapies to each patient’s cancer. The organization supports patients with its in-house Park Pharmacy, which stocks oncology and hematology medications and handles insurance, prior authorizations, co-pays, and 24/7 pharmacist access. It differentiates itself by combining extensive community-based care with a sizable research network and a partnership with OneOncology, enabling broad access to trials and advanced care at convenient locations. The goal is to provide high-quality cancer care and access to clinical research close to patients’ homes.

Company Size

501-1,000

Company Stage

Debt Financing

Total Funding

$98.3M

Headquarters

Nashville, Tennessee

Founded

1976

Get referred to Tennessee Oncology

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • The new 56,000 sq ft Murfreesboro center will open in spring 2027, expanding access.
  • Partnership with SOPHiA GENETICS enhances genomic data integration for precision medicine and trial matching.
  • Johnson City clinic opened in November 2024, reducing patient travel in the Tri-Cities region.

What critics are saying

  • 340B drug reform will cut pharmacy margins by 15–25% if federal pricing rules tighten in 12 months.
  • New executive mandates could force 20–30% higher administrative overhead and delay patient access within 6 months.
  • Rapid expansion across three new centers may overextend operations and delay ROI in 12–24 months.

What makes Tennessee Oncology unique

  • Tennessee Oncology treats nearly half of Tennessee's cancer patients across 36 clinics.
  • The practice operates one of the nation's leading clinical trial networks for community oncology.
  • It launched CAR-T therapy and an early-phase unit to expand advanced blood cancer access.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

10%

1 year growth

10%

2 year growth

10%
Tennessee Oncology
Sep 24th, 2025
Tennessee Oncology Breaks Ground on State-of-the-Art Medical Center in Tullahoma

Tennessee Oncology breaks ground on state-of-the-art Medical Center in Tullahoma. Tennessee Oncology recently broke ground a new state-of-the-art medical center in Tullahoma. Located on a three-acre campus, the 33,000 square foot center will bring together medical oncology, radiation oncology, and imaging services - offering patients comprehensive, coordinated cancer care in one location, close to home. "The official groundbreaking of the Tullahoma Medical Center is more than the start of construction - it is a continuation of a mission, a vision, and a legacy of compassionate care for the Tullahoma community," said Natalie Dickson, MD, President and CEO of Tennessee Oncology. "This new facility represents a bold step forward for Tullahoma. Together, with Dr. Ryan Carr, Dr. Nnamdi Eze, Dr. John Phillips, Dr. Brian Schlick, and Dr. Mark Sittig, we are laying the foundation for something that will make a lasting impact. This center will not only provide critical care to patients, but it will also stand as a symbol of hope, healing, and the enduring strength of this community." The Tullahoma Medical Center is a continuation of the incredible legacy of Dr. Mainuddin Ahmed and Dr. Adil Mohyuddin, whose commitment to oncology care in the Tullahoma region laid the foundation for the care Tnoncology provide patients today. This new medical center represents the heart of its mission at Tennessee Oncology - bringing world-class cancer care closer to the communities that need it most. Its investment in the Tullahoma Medical Center reflects its commitment to expanding access, supporting local patients, and delivering compassionate care where it matters. Tennessee Oncology extends a sincere thank-you to Jason Quick, the Tullahoma City Administrator, and Kathryn Wiseman of the Tullahoma Area Chamber of Commerce. Their dedication to the community and support of this project have been instrumental.

PR Newswire
Mar 10th, 2025
Tennessee Oncology Appoints Dr. Casey Chollet-Lipscomb As Chief Medical Officer

NASHVILLE, Tenn., March 10, 2025 /PRNewswire/ -- Tennessee Oncology, a nationally recognized independent oncology practice that treats nearly half of the cancer patients in the state across 36 clinics, is pleased to announce the appointment of Casey Chollet-Lipscomb, MD, as its new Chief Medical Officer

PR Newswire
Dec 3rd, 2024
Oneoncology Partner Practice Investigators To Present 26 Abstracts At Ash Annual Meeting

NASHVILLE, Tenn., Dec. 3, 2024 /PRNewswire/ -- OneOncology, a physician-led platform dedicated to advancing independent community oncology practices, and the OneOncology Research Network (OneR), its clinical research site management organization, proudly recognize the outstanding research contributions of its partner practice investigators from The Cancer and Hematology Centers in Michigan, New York Cancer Blood Specialists and Tennessee Oncology, who will showcase a total of 26 oral and poster presentations at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 7–10, 2024

Impact Newswire
Nov 22nd, 2024
SOPHiA GENETICS Announces Expanded Partnership with Tennessee Oncology

SOPHiA GENETICS announces expanded partnership with Tennessee Oncology.

PR Newswire
Nov 5th, 2024
Tennessee Oncology Expands Cancer Care With New Clinic In Johnson City

NASHVILLE, Tenn., Nov. 5, 2024 /PRNewswire/ -- Tennessee Oncology, a nationally recognized independent oncology practice that cares for nearly half of Tennessee's cancer patients across 36 locations, proudly announces the opening of its new cancer care center in Johnson City. The clinic will be staffed by Jamal Maatouk, MD, Teresa Lord, MD, and a dedicated 30-member care team. "Expanding access to cancer care in Johnson City enables Tennessee Oncology to deliver world-class cancer treatment to the Tri-Cities region, eliminating the need for patients to travel long distances for the same high-quality care as they would receive in Nashville or Chattanooga," said Natalie Dickson, MD, President and Chief Executive Officer of Tennessee Oncology. "We are thrilled to welcome Dr. Maatouk and Dr